Recombinant Poxvirus and the tumor microenvironment: Oncolysis, immune regulation and immunization

Daniel W. Sharp, Edmund C. Lattime

Research output: Contribution to journalReview articlepeer-review

19 Scopus citations


Oncolytic viruses (OVs) are being extensively studied for their potential roles in the development of cancer therapy regimens. In addition to their direct lytic effects, OVs can initiate and drive systemic antitumor immunity indirectly via release of tumor antigen, as well as by encoding and delivering immunostimulatory molecules. This combination makes them an effective platform for the development of immunotherapeutic strategies beyond their primary lytic function. Engineering the viruses to also express tumor-associated antigens (TAAs) allows them to simultaneously serve as therapeutic vaccines, targeting and amplifying an immune response to TAAs. Our group and others have shown that vaccinating intratumorally with a poxvirus that encodes TAAs, in addition to immune stimulatory molecules, can modulate the tumor microenvironment, overcome immune inhibitory pathways, and drive both local and systemic tumor specific immune responses.

Original languageEnglish (US)
Article number19
Issue number3
StatePublished - Sep 1 2016

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)


  • GM-CSF (granulocyte-macrophage colony-stimulating factor)
  • Immunotherapy
  • Oncolytic viruses
  • Poxvirus
  • TRICOM (triad of costimulatory molecules)
  • Tumor microenvironment
  • Vaccinia


Dive into the research topics of 'Recombinant Poxvirus and the tumor microenvironment: Oncolysis, immune regulation and immunization'. Together they form a unique fingerprint.

Cite this